Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGSNASDAQ:AYTUNASDAQ:CVKDNASDAQ:KZR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$4.48-8.0%$7.41$3.76▼$46.80$29.78M2.76193,783 shs137,572 shsAYTUAytu BioPharma$1.25+3.1%$1.16$0.95▼$3.45$7.71M-0.129,162 shs18,321 shsCVKDCadrenal Therapeutics$14.25-8.1%$16.90$5.70▼$22.90$27.65M1.4639,475 shs38,425 shsKZRKezar Life Sciences$4.32+4.9%$4.81$3.62▼$9.18$31.56M0.6159,181 shs137,263 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-7.72%-20.00%-10.93%-83.73%-77.12%AYTUAytu BioPharma+0.81%-4.57%+17.92%-19.35%-60.32%CVKDCadrenal Therapeutics-8.97%-13.37%-5.00%-23.80%+1,424,999,900.00%KZRKezar Life Sciences+4.47%-4.00%+5.37%-29.87%-47.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics3.8265 of 5 stars3.51.00.04.82.41.70.6AYTUAytu BioPharma0.9057 of 5 stars0.03.00.03.40.01.70.6CVKDCadrenal Therapeutics2.7095 of 5 stars3.55.00.00.01.11.70.6KZRKezar Life Sciences3.6876 of 5 stars3.23.00.04.60.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.001,462.50% UpsideAYTUAytu BioPharma 0.00N/AN/AN/ACVKDCadrenal Therapeutics 3.00Buy$32.00124.56% UpsideKZRKezar Life Sciences 2.33Hold$39.50814.35% UpsideCurrent Analyst Ratings BreakdownLatest AYTU, CVKD, KZR, and ALGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/11/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.002/28/2025KZRKezar Life SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Outperform(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.27M8.38N/AN/A$30.65 per share0.15AYTUAytu BioPharma$77.23M0.10N/AN/A$4.64 per share0.27CVKDCadrenal TherapeuticsN/AN/AN/AN/A$8.86 per shareN/AKZRKezar Life Sciences$7M4.51N/AN/A$25.80 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$87.68M-$17.51N/AN/AN/A-1,283.19%-114.34%-64.58%N/AAYTUAytu BioPharma-$15.84M-$1.45N/A∞N/A-7.62%-19.30%-4.80%5/14/2025 (Estimated)CVKDCadrenal Therapeutics-$8.36M-$8.67N/AN/AN/AN/A-142.95%-118.40%N/AKZRKezar Life Sciences-$101.87M-$11.55N/AN/AN/AN/A-54.95%-46.11%N/ALatest AYTU, CVKD, KZR, and ALGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/A5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million3/25/2025Q4 2024 & Study ResultKZRKezar Life Sciences-$2.71-$2.77-$0.06-$2.77N/AN/A3/13/2025Q4 2024CVKDCadrenal Therapeutics-$1.71-$2.74-$1.03-$2.74N/AN/A3/10/2025Q4 2024ALGSAligos Therapeutics-$2.63-$13.08-$10.45-$13.08$0.43 million$0.63 million2/12/2025Q2 2025AYTUAytu BioPharmaN/A-$0.28N/A-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A3.813.81AYTUAytu BioPharma0.320.980.81CVKDCadrenal TherapeuticsN/A3.693.69KZRKezar Life Sciences0.057.657.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%AYTUAytu BioPharma33.49%CVKDCadrenal Therapeutics7.92%KZRKezar Life Sciences67.90%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics8.75%AYTUAytu BioPharma3.60%CVKDCadrenal Therapeutics48.62%KZRKezar Life Sciences10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million3.27 millionNo DataAYTUAytu BioPharma1606.17 million6.00 millionNot OptionableCVKDCadrenal Therapeutics41.94 million916,000Not OptionableKZRKezar Life Sciences607.31 million6.62 millionNot OptionableAYTU, CVKD, KZR, and ALGS HeadlinesRecent News About These CompaniesKezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on ThursdayMay 1, 2025 | americanbankingnews.comKezar toplines small Phase 2a dataset in autoimmune liver diseaseMarch 27, 2025 | endpts.comKezar Life Sciences price target lowered to $7 from $9 at Wells FargoMarch 27, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)March 26, 2025 | markets.businessinsider.comKezar Life Sciences reports topline results from PORTOLA trialMarch 26, 2025 | markets.businessinsider.comKezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)March 25, 2025 | seekingalpha.comKezar drops after Q4 results and mid-stage data for lead assetMarch 25, 2025 | msn.comKezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial ResultsMarch 25, 2025 | businesswire.comKezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025March 24, 2025 | businesswire.comTD Cowen Keeps Their Buy Rating on Kezar Life Sciences (KZR)February 28, 2025 | markets.businessinsider.comPositive Report for Kezar Life Sciences (KZR) from William BlairFebruary 28, 2025 | markets.businessinsider.comWilliam Blair Sticks to Its Hold Rating for Kezar Life Sciences (KZR)February 25, 2025 | markets.businessinsider.comKezar Life Sciences files $400M mixed securities shelfFebruary 6, 2025 | markets.businessinsider.com(KZR) Investment AnalysisJanuary 1, 2025 | news.stocktradersdaily.comKezar Life Sciences price target lowered to $9 from $11 at Wells FargoDecember 19, 2024 | markets.businessinsider.comTrend Tracker for (KZR)December 10, 2024 | news.stocktradersdaily.comKezar Life Sciences updates shareholder rights agreementDecember 5, 2024 | investing.comKezar Life Sciences (KZR) Receives a Hold from H.C. WainwrightDecember 2, 2024 | markets.businessinsider.comWhen the Price of (KZR) Talks, People ListenNovember 20, 2024 | news.stocktradersdaily.comKezar struck again with second FDA holdNovember 14, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYTU, CVKD, KZR, and ALGS Company DescriptionsAligos Therapeutics NASDAQ:ALGS$4.48 -0.39 (-8.01%) As of 05/9/2025 04:00 PM EasternAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Aytu BioPharma NASDAQ:AYTU$1.25 +0.04 (+3.05%) As of 05/9/2025 03:47 PM EasternAytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Cadrenal Therapeutics NASDAQ:CVKD$14.25 -1.25 (-8.06%) As of 05/9/2025 03:43 PM EasternCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Kezar Life Sciences NASDAQ:KZR$4.32 +0.20 (+4.85%) As of 05/9/2025 03:58 PM EasternKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
